1. Outcome of Transplantation for Acute Myelogenous Leukemia in Children with Down Syndrome 
Johann K. Hitzler, Wensheng He, John Doyle, Mitchell Cairo, Bruce M. Camitta, Ka Wah Chan, Miguel A. Diaz Perez, Christopher Fraser, Thomas G. Gross, John T. Horan, Alana A. Kennedy-Nasser, Carrie Kitko, Joanne Kurtzberg, Leslie Lehmann, Tracey O'Brien, Michael A. Pulsipher, Franklin O. Smith, Mei-Jie Zhang, Mary Eapen, Paul A. Carpenter 
Biology of Blood and Marrow Transplantation 
Volume 19, Issue 6, Pages (June 2013)
DOI: /j.bbmt
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
(A) The 3-year probabilities of TRM: 24% (95% CI, 9% to 44%) and 15% (95% CI, 8% to 24%) for DS-AML and non-DS AML, respectively (P = .04). (B) The 3-year probabilities of relapse: 62% (95% CI, 41% to 81%) and 37% (95% CI, 27% to 48%), for DS-AML and non-DS AML, respectively (P < .001). (C) The 3-year probabilities of DFS: 14% (95% CI, 3% to 32%) and 48% (95% CI, 37% to 59%) for DS-AML and non-DS AML, respectively (P < .001). (D) The 3-year probabilities of overall survival: 21% (95% CI, 6% to 42%) and 52% (95% CI, 41% to 63%), for DS-AML and non-DS AML, respectively (P < .001).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions